About TheraSphere®

 

TheraSphere® acts predominantly through radiation vs. embolization, and its unique properties, including high activity per sphere, enable high absorbed dose coverage to the tumor. The ability of TheraSphere® to selectively deliver a high absorbed dose to the tumor without compromising patient safety is fundamental to achieving improved patient outcomes. The observation that improved responses are seen above certain absorbed dose thresholds opens the way for personalized dosimetry with glass microspheres, with the ultimate goal of optimizing dose according to patient-specific tumor characteristics


The properties of TheraSphere® also allow for unique treatment options in the clinic. Not being limited by the number of microspheres provides flexibility to adjust radiation dose according to individual patient needs, enabling clinical utility for downstaging, bridge to transplant, and radiation segmentectomy. TheraSphere® has demonstrated treatment success in a range of scenarios: curative or palliative, livers with single or multifocal tumors, portal vein thrombosis (PVT), and using segmental or lobar approaches.3–8

More information

Recently published 2016 European Society for Medical Oncology (ESMO) Clinical Guidelines recommend selective internal radiation therapy (SIRT) or transarterial radioembolization (TARE) with 90Y microspheres for the treatment of colorectal cancer liver metastasis and inoperable intrahepatic cholangiocarcinoma, complementing existing guidelines for SIRT/TARE use in HCC.47–49